Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
| ▸ | MMP7 | P09237 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP12 | P39900 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 3/20 | 0.55 |
| ▸ | CPA1 | P15085 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10932308 | 1.00 | MME (0.66) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL17026706 | 1.00 | MME (0.66) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL14567243 | 0.91 | PSMB5 (0.55) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL10891120 | 0.88 | MME (0.60) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL10959619 | 0.87 | MME (0.63) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL10954197 | 0.87 | MME (0.63) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL10950123 | 0.87 | MME (0.63) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL10662173 | 0.86 | MME (0.58) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL9069255 | 0.85 | MME (0.71) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL7292059 | 0.85 | MME (0.71) | MMELTA4HMMP2MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-8071556-B2 | Peptide substance revealing a stress protective effect, pharmaceutical composition on its base, and the method of its application | Obschestvo S Ogranichennoi Otvetstevennostyu “Sia Peptides” (RU) | 2011-12-06 | — | — | US | disclosed |
| US-20090105158-A1 | PEPTIDE SUBSTANCE REVEALING A STRESS PROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE, AND THE METHOD OF ITS APPLICATION | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "SIA PEPTIDES" (RU) | 2009-04-23 | — | — | US | disclosed |
| EP-2021353-A2 | PEPTIDE SUBSTANCE REVEALING A STRESS PROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION | Obschestvo S Ogranichennoi Otvetstvennostyu "sia Peptides" (RU) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007136295-A2 | PEPTIDE SUBSTANCE REVEALING A STRESS PROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU 'SIA PEPTIDES' (RU) | 2007-11-29 | — | — | WO | disclosed |
| EP-0396719-B1 | NEURITE GROWTH REGULATORY FACTORS | ZUERICH ERZIEHUNGSDIREKTION (CH) | 1995-07-05 | — | — | EP | disclosed |
| US-5250414-A | Metalloendoprotease cleavage of tetrapeptide | ERZIEHUNGSDIREKTION OF THE CANTON ZURICH (CH) | 1993-10-05 | — | — | US | disclosed |
| WO-1993000427-A2 | NEURITE GROWTH REGULATORY FACTORS | ERZIEHUNGSDIREKTION OF THE CANTON ZURICH (CH) | 1993-01-07 | — | — | WO | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
| EP-0396719-A1 | NEURITE GROWTH REGULATORY FACTORS. | 3 G CORP (CH) | 1990-11-14 | — | — | EP | disclosed |
| WO-1990005191-A1 | NEURITE GROWTH REGULATORY FACTORS | ERZIEHUNGSDIREKTION OF THE CANTON ZURICH (CH) | 1990-05-17 | — | — | WO | disclosed |
| US-4513009-A | GLYCINE, ALANINE AND SERINE DERIVATIVES | SOCIETE CIVILE BIOPROJET (FR) | 1985-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105158-A1 | PEPTIDE SUBSTANCE REVEALING A STRESS PROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE, AND THE METHOD OF ITS APPLICATION | NGLY1, VIP, GLUL | MME 448/4885LTA4H 1609/4885MMP2 2600/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | MME 182/4885LTA4H 320/4885MMP2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.